Bickers J, Benjamin R, Wilson H, Eyre H, Hewlett J, McCredie K
Cancer Treat Rep. 1981 May-Jun;65(5-6):427-30.
Rubidazone, a new anthracycline antibiotic, is the benzoyl hydrazone derivative of daunorubicin. The Southwest Oncology Group carried out a phase II study of the drug in 126 patients with previously treated acute leukemia; 116 patients were evaluable. Good-risk patients were given doses of 450 mg/m2, and poor-risk patients were given doses of 300 mg/m2 approximately every 3 weeks. No complete response was observed in 25 patients with chronic myelocytic leukemia blast cell transformation. In the remaining patients the overall complete response rate was 22% and the rate of complete plus partial response was 29%. In good-risk patients these rates were 27% and 35%, respectively. Toxicity was similar to that observed with other anthracyclines except that acute febrile reactions were more pronounced. On the basis of the results, there are plans for a large-scale comparison study of rubidazone versus doxorubicin, each in combination with cytarabine, vincristine, and prednisone.
鲁比达唑，一种新的蒽环类抗生素，是柔红霉素的苯甲酰腙衍生物。西南肿瘤协作组对126例曾接受过治疗的急性白血病患者进行了该药的II期研究；116例患者可进行评估。高危患者每3周左右给予450mg/m²的剂量，低危患者给予300mg/m²的剂量。25例慢性粒细胞白血病急变患者未观察到完全缓解。在其余患者中，总体完全缓解率为22%，完全缓解加部分缓解率为29%。在高危患者中，这些率分别为27%和35%。毒性与其他蒽环类药物观察到的相似，只是急性发热反应更为明显。基于这些结果，计划进行一项大规模的鲁比达唑与多柔比星对比研究，二者均与阿糖胞苷、长春新碱和泼尼松联合使用。
